From Investment to Impact: The ROI of Tailored Obesity Care
- Case Study
- Obesity care and GLP-1s
Summary
As organizations seek solutions to combat the rising costs associated with obesity, attention has turned to promising new treatments such as GLP-1s. However, implementing these therapies is not without its challenges; foremost among them is the extraordinarily high cost of these medications in the United States.
For organizations who still want to cover brand name GLP-1 medications while effectively mitigating costs, Noom Med offers a revolutionary solution that pairs biology and psychology to rightsize GLP-1 use, drive better outcomes, and lower overall costs.
Offering a compelling projected 4.1X ROI for an organization with 20,000 employees, Noom Med addresses the root of the problem — uncontrolled healthcare spending — while improving employee health outcomes.
Download the ROI breakdown to learn how Noom Med slashes unnecessary costs while also ensuring that GLP-1 medications are used optimally, maximizing their benefits while minimizing waste.
Download the Free Report
"*" indicates required fields
By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.
Bring Noom to
your organization
Give your workforce a preview of what’s possible
for their physical and mental health.
